Synageva BioPharma (GEVA) Begins SBC-103 Phase 1/2 Dosing in MPS IIIB Patients
Tweet Send to a Friend
Synageva BioPharma (Nasdaq: GEVA) announced dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
